Viruses are the ultimate parasites as they derive nutrition from the host cell and also hijack and direct its metabolic machinery to synthesize new virus particles. Viruses can live and replicate only inside host body. Anti-viral drugs are specifically used to treat viral infections and act mostly by inhibiting their target viruses. The growth of antiviral drugs market is driven by factors such as rise in healthcare expenditure, growing research and development investment, emergence of virus life-threatening diseases like bird flu, strong development pipeline and increasing incidence rates of viral infections particularly HIV. WHO estimates 36.7 million people are suffering from HIV/AIDS worldwide with 1.1 million deaths of AIDS-related illnesses in 2015.
Get Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/2454
Taking all these factors the market for anti-viral drugs is expected to reach $62.67 billion by the end of the forecast period growing at a CAGR of 6.9%.
Anti-viral drugs are used to treat viral infections and are the only agents acting against viruses as either other drugs are ineffective or too toxic. The market segment of anti-viral drugs is driven by factors such as rise in healthcare expenditure, growing research and development investment, emergence of virus life-threatening diseases like bird flu, strong development pipeline and increasing incidence rates of viral infections particularly HIV. WHO has estimated that in 2015 about 36.7 million people are suffering from HIV/AIDS with 1.1 million deaths occurring due to AIDS-related illness the emergence of donor funding in the treatment of the disease has also increased the demands of anti-viral drug market. Strong research pipeline coupled with rise in research and development investment will be the market driver of the future.
The constraints on the market include side effects associated with treatment, the cost of the therapy and poor efficacy and effectiveness of the drugs.
The major participants of this market are: Johnson & Johnson, Merck & Co. Inc., Gilead Sciences Inc., Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Abbott Laboratories, Novartis International AG, AstraZeneca AB, Cipla Inc. and others.
Global anti-viral drugs market has been segmented on the basis of on the basis of application, which comprises hepatitis, HIV/AIDS, herpes, influenza and others. On the basis of mechanism of action; market is segmented into nucleotide polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors and others.
Depending on geographic region, anti-viral drugs market is segmented into four key regions: America, Europe, Asia Pacific, and Middle East & Africa. Globally, America is the largest market for anti-viral drugs with Europe tied for the second space. Asia Pacific region is expected to be fastest growing region in anti-viral drugs market.
Browse Complete 84 Pages Premium Research Report Enabled with Respective Tables and Figures at @ https://www.marketresearchfuture.com/reports/anti-viral-drugs-market-2454
Table Of Contents
1.2 Scope Of Study
1.3 Research Objective
1.4 Assumptions & Limitations
1.5 Market Structure:
2 Research Methodology
2.1 Research Process
2.2 Primary Research
2.3 Secondary Research
3 Market Dynamics
3.5 Macroeconomic Indicators
4 Market Factor Analysis
4.1 Porter’s Five Forces Model
4.1.1 Bargaining Power Of Suppliers
4.1.2 Bargaining Power Of Customer
4.1.3 Intensity Of Competitor’s
4.1.4 Threat Of New Entrants
Send an Enquiry @ https://www.marketresearchfuture.com/enquiry/2454
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Phone: +1 646 845 9312